Carolien A M Koeleman
Overview
Explore the profile of Carolien A M Koeleman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
2208
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Falck D, Sokolova M, Koeleman C, Irumva V, Kirchner P, Schulz S, et al.
Cell Commun Signal
. 2025 Feb;
23(1):92.
PMID: 39962487
Background: Glycosylation is an important posttranslational modification of proteins and in most cases indispensable for proper protein function. Like most soluble proteins, IgA, the second most prevalent antibody in human...
2.
Visconti A, Rossi N, Bondt A, Ederveen A, Thareja G, Koeleman C, et al.
Genome Med
. 2024 Aug;
16(1):96.
PMID: 39123268
Background: Immunoglobulin (Ig) glycosylation modulates the immune response and plays a critical role in ageing and diseases. Studies have mainly focused on IgG glycosylation, and little is known about the...
3.
Yaykasli K, van Schie K, Toes R, Wuhrer M, Koeleman C, Bila G, et al.
Int J Mol Sci
. 2024 Jun;
25(12).
PMID: 38928183
Sepsis is a life-threatening condition with a rising disease burden worldwide. It is a multifactorial disease and is defined as a dysregulated host response to infection. Neutrophils have been shown...
4.
de Graaf E, Larsen M, van der Bolt N, Visser R, Verhagen O, Hipgrave Ederveen A, et al.
Immunology
. 2023 Dec;
171(3):428-439.
PMID: 38097893
The type and strength of effector functions mediated by immunoglobulin G (IgG) antibodies rely on the subclass and the composition of the N297 glycan. Glycosylation analysis of both bulk and...
5.
Clerc F, Reiding K, de Haan N, Koeleman C, Hipgrave Ederveen A, Manetti N, et al.
J Proteome Res
. 2023 Aug;
22(10):3213-3224.
PMID: 37641533
Inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), are chronic and relapsing inflammations of the digestive tract with increasing prevalence, yet they have unknown origins...
6.
Holborough-Kerkvliet M, Mucignato G, Moons S, Psomiadou V, Konada R, Pedowitz N, et al.
Glycobiology
. 2023 Jul;
33(9):732-744.
PMID: 37498177
Glycans play a pivotal role in biology. However, because of the low-affinity of glycan-protein interactions, many interaction pairs remain unknown. Two important glycoproteins involved in B-cell biology are the B-cell...
7.
Volkov M, Brinkhaus M, van Schie K, Bondt A, Kissel T, van der Kooi E, et al.
J Immunol
. 2022 Dec;
210(2):158-167.
PMID: 36480251
Abs can be glycosylated in both their Fc and Fab regions with marked effects on Ab function and binding. High levels of IgG Fab glycosylation are associated with malignant and...
8.
Falck D, Lechmann M, Momcilovic A, Thomann M, Koeleman C, Jany C, et al.
MAbs
. 2022 Nov;
14(1):2145929.
PMID: 36383465
A relatively low clearance is one of the prominent favorable features of immunoglobulin G1-based therapeutic monoclonal antibodies (mAbs). Various studies have observed differential clearance of mAb glycoforms, including oligomannose glycoforms,...
9.
van Osch T, Steuten J, Nouta J, Koeleman C, Bentlage A, Heidt S, et al.
Platelets
. 2022 Oct;
34(1):2129604.
PMID: 36185007
Immune-mediated platelet refractoriness (PR) remains a significant problem in the setting of platelet transfusion and is predominantly caused by the presence of alloantibodies directed against class I human leukocyte antigens...
10.
van Osch T, Oosterhoff J, Bentlage A, Nouta J, Koeleman C, Geerdes D, et al.
Haematologica
. 2022 Mar;
107(10):2432-2444.
PMID: 35354253
Approximately 20% of patients receiving multiple platelet transfusions develop platelet alloantibodies, which can be directed against human leukocyte antigens (HLA) and, to a lesser extent, against human platelet antigens (HPA)....